Bristol-Myers Squibb's Big Bet on ImClone
News posting on August 01, 2008 | Related to Adnexus Therapeutics
ImClone’s pipeline of cancer-fighting compounds could fill a big gap in Bristol’s portfolio after key drugs go off patent, say analysts
About Adnexus Therapeutics
Adnexus discovers and develops a novel, proprietary class of targeted biologics called Adnectinsô. We belie... Find out more
